<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349102</url>
  </required_header>
  <id_info>
    <org_study_id>GATING 2006</org_study_id>
    <secondary_id>ET2005-052</secondary_id>
    <nct_id>NCT00349102</nct_id>
  </id_info>
  <brief_title>Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer</brief_title>
  <official_title>Evaluation of the Interest of Breath Holding for the Prevention of Radiation Pneumonitis Following Conformal Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the interest of breath holding for the prevention of
      radiation pneumonitis following conformal radiation therapy.

      Eligible patients will be randomly assigned in a 2-arm trial to free breathing or breath
      holding during conformal radiation.

      The primary objective of the study is to establish the efficacy of breath holding, compared
      to free breathing, in the prevention of early pulmonary toxicity following conformal
      radiation.

      Several departments of radiotherapy, many pneumology units and two basic and applied research
      laboratories take part in this multicentric study.

      The number of patients required to demonstrate a reduction in radiation pneumonitis from 45 %
      to 22.5 %, assuming an alpha risk of 5% in a two-sided test and 95% power, is 240 (120 per
      arm). With a planned accrual of 7 patients per month, it is estimated that the inclusion
      period should be approximately 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives are:

        -  Validation of the Lent-Soma toxicity scale by comparison to the RTOG scale,

        -  Response rate at different times: week 6-8, 1 year and 2 years after the end of
           irradiation,

        -  Progression-free survival rate at 1 year and 2 years after the end of irradiation

        -  Confirmation of the predictive value of serum cytokine levels (IL-6 and IL-10) during
           irradiation for the occurrence of early radiation toxicity, and analysis of the
           correlation between these serum levels at inclusion and the expression polymorphism of
           candidate genes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2006</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical, functional and radiological evaluations at 6-8 weeks and 10-12 weeks after the end of irradiation</measure>
    <time_frame>6-8 and 10-12 weeks after the end of irradiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RTOG and LENT-SOMA scores at 6-8 weeks and 10-12 weeks after the end of irradiation, response rates at 6-8 weeks, 1 year and 2 years after irradiation</measure>
    <time_frame>6-8 and 10-12 weeks after the end of irradiation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Carcinoma, Non-small-cell Lung</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Free breathing during conformal radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breath holding during conformal radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Free breathing</intervention_name>
    <description>Free breathing during conformal radiation</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Conformal radiation</other_name>
    <other_name>Lung cancer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Breath holding</intervention_name>
    <description>Breath holding during conformal radiation</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Conformal radiation</other_name>
    <other_name>Lung cancer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-metastatic cytologically or histologically proven non-small-cell lung cancer
             (NSCLC)

          -  Operated NSCLC patients requiring post-surgical irradiation or non-operated NSCLC
             patients requiring curative irradiation

          -  Conformational thoracic radiotherapy with curative intent

          -  Age &gt;= 18

          -  Complete functional respiratory evaluation (FRE) performed less than 2 months before
             inclusion, demonstrating a maximum expiratory flow-volume/second &gt; 1 l (in case
             surgery, the FRE must have been realized in the post-surgery period)

          -  Thoracic CT-scan performed less than 2 months before inclusion for non-operated
             patient

          -  PET-scan performed less than 2 months before inclusion for non-operated patient

          -  Performance status (PS) ECOG &lt;= 1

          -  Possible training on breath holding technique

          -  Female patients of childbearing potential: effective method of contraception necessary

          -  Mandatory affiliation with a social security system

          -  Written, signed, informed consent

        Exclusion Criteria:

          -  Small-cell lung cancer

          -  Metastatic disease

          -  Infiltrating pulmonary disease

          -  Previous thoracic irradiation

          -  Indication of irradiation with palliative intent

          -  Previous or concurrent primary malignancies at other sites (except basocellular skin
             cancer or cervical cancer in situ or complete remission for more than 5 years)

          -  Life expectancy &lt; 6 months

          -  Patient understanding incompatible with the breath-hold technique (patients with major
             presbycusis are not eligible)

          -  Pregnant or lactating woman

          -  Patient included in another clinical trial

          -  Follow-up difficult

          -  Patient deprived of freedom
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Line CLAUDE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard, Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lafay I, Ginestet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin JC, Cordier JF, Carrie C. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol. 2005 Dec 1;23(34):8748-56.</citation>
    <PMID>16314635</PMID>
  </reference>
  <reference>
    <citation>Claude L, Pérol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004 May;71(2):175-81.</citation>
    <PMID>15110451</PMID>
  </reference>
  <results_reference>
    <citation>L. Falchero, D. Perol, D. Arpin, M. Vincent, M. Perol, JF. Cordier, D. Boutry, I. Martel-Lafay, C. Carrie.- Conséquences fonctionnelles de la radiothérapie thoracique conformationnelle (r3d) et facteurs prédictifs de pneumopathie radique aiguë (PRA) chez des patients atteints de cancer bronchique non à petites cellules (CNPC). Rev. Mal. Resp., 2001 ; 18 (suppl) : 1S102</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>Breath-hold</keyword>
  <keyword>Radiation pneumonitis</keyword>
  <keyword>Serum cytokines</keyword>
  <keyword>LENT-SOMA scale</keyword>
  <keyword>Non-metastatic non-small-cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

